Khan, A, Fawcett, J, Lichtenberg, P, Kirsch, I, Brown, WA. A systematic review of comparative efficacy of treatments and controls for depression. PLoS One
2012; 7: e41778.
Kirsch, I, Deacon, BJ, Huedo-Medina, TB, Scoboria, A, Moore, TJ, Johnson, BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med
2008; 5: e45.
Khan, A, Redding, N, Brown, WA. The persistence of the placebo response in antidepressant clinical trials. J Psychiatr Res
2008; 42: 791–6.
Khan, A, Bhat, A, Kolts, R, Thase, ME, Brown, W. Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades?
CNS Neurosci Ther
2010; 16: 217–26.
Walsh, BT, Seidman, SN, Sysko, R, Gould, M. Placebo response in studies of major depression: variable, substantial and growing. JAMA
2002; 287: 1840–7.
Kirsch, I. Conditioning, expectancy, and the placebo effect: comment on Stewart-Williams and Podd. Psychol Bull
2004; 130: 341–3,
Sotsky, SM, Glass, DR, Shea, MT, Pilkonis, PA, Collins, JF, Elkin, I, et al. Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry
1991; 148: 997–1008.
Sheehan, DV, Lecrubier, Y, Sheehan, KH, Amorim, P, Janavs, J, Weiller, E, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psych
1998; 59 (suppl 20); 22–33.
Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry
1960; 23: 56–62.
Fawcett, J, Epstein, P, Fiester, SJ, Elkin, I, Autry, JH. Clinical management – imipramine/placebo administration manual: NIMH Treatment of Depression Collaboration Research Program. Psychopharmacol Bull
1987; 23: 309–24.
Elkin, I, Parloff, MB, Hadley, SW, Autry, JH. NIMH Treatment of Depression Collaborative Research Program. Background and research plan. Arch Gen Psychiatry
1985; 42: 305–16.
Weiss, M, Gaston, L, Propst, A, Wisebord, S, Zicherman, V. The role of the alliance in the pharmacologic treatment of depression. J Clin Psychiatry
1997; 58: 196–204.
Su, L. A marginalized conditional linear model for longitudinal binary data when informative dropout occurs in continuous time. Biostatistics
2012; 13: 355–68.
Enders, CK, Badalos, DL. The relative performance of full information maximum likelihood estimation for missing data in structural equation models. Struct Equ Modeling
2001; 8: 430–57.
Krell, HV, Leuchter, AF, Morgan, M, Cook, IA, Abrams, M. Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. J Clin Psychiatry
2004; 65: 1174–9.
Brunoni, AR, Lopes, M, Kaptchuk, TJ, Fregni, F. Placebo response of nonpharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS One
2009; 4: e4824.
Diederich, NJ, Goetz, CG. The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology
2008; 71: 677–84.
Rutherford, BR, Sneed, JR, Roose, SP. Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom
2009; 78: 172–81.
Papakostas, GI, Fava, M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol
2009; 19: 34–40.
Sinyor, M, Levitt, AJ, Cheung, AH, Schaffer, A, Kiss, A, Dowlati, Y, et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry
2010; 71: 270–9.
Rutherford, BR, Marcus, SM, Wang, P, Sneed, JR, Pelton, G, Devanand, D, et al. A randomized, prospective pilot study of patient expectancy and antidepressant outcome. Psychol Med
2013; 43: 975–82.
Fountoulakis, KN, Möller, HJ. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol
2011; 14: 405–12.
Lindsley, CW. The top prescription drugs of 2011 in the United States: antipsychotics and antidepressants once again lead CNS therapeutics. ACS Chem Neurosci
2012; 3: 630–1.
Rosenthal, MB, Berndt, ER, Donohue, JM, Epstein, AM, Frank, RG. Demand effects of recent changes in prescription drug promotion. In Frontiers in Health Policy Research (Vol 6) (eds Cutler, DM, Garber, AM): 1–27. National Bureau of Economic Research, 2003.
Leuchter, RK. From cocaine to viagra: a social and economic analysis of the pharmaceutical industry. In Honors Theses-All: 939. Wesleyan University, 2012.
Gilbody, S, Wilson, P, Watt, I. Benefits and harms of direct to consumer advertising: a systematic review. Qual Saf Health Care
2005; 14: 246–50.
Metzl, JM. If direct-to-consumer advertisements come to Europe: lessons from the American marketplace. Lancet
2007; 369: 704–6.
Iacoviello, BM, McCarthy, KS, Barrett, MS, Rynn, M, Gallop, R, Barber, JP. Treatment preferences affect the therapeutic alliance: implications for randomized controlled trials. J Consult Clin Psychol
2007; 75: 194–8.
Strunk, DR, Stewart, MO, Hollon, SD, DeRubeis, RJ, Fawcett, J, Amsterdam, JD, et al. Can pharmacotherapists be too supportive? A process study of active medication and placebo in the treatment of depression. Psychol Med
2010; 40: 1379–87.
Posternak, MA, Zimmerman, M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br J Psychiatry
2007; 190: 287–92.